GSK Unveils new Montrose facility

Pharmaceutical giant GSK has unveiled its £44 million vaccine production facility in Montrose.

The site, which will produce ingredients for vaccines to treat conditions such as tetanus, pneumonia and whooping cough, has been five years in the making. GSK had first announced plans for its facility, which is now being commissioned, in 2012.

The facility will create a further 19 skilled jobs in Montrose by the time it is fully operational in 2019, increasing GSK’s current 450-strong headcount in the Angus town. It will manufacture sterile aluminium salts – compounds which boost the human body’s response to vaccines.

Read the full story here.